What Is Claimed Is:

- 1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:40 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;
- (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:161 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;
- (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:161 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;
- (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:161or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40;
- (e) a polynucleotide encoding a polypeptide of SEQ ID NO:161 or the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40, having biological activity;
 - (f) a polynucleotide which is a variant of SEQ ID NO:40;
 - (g) a polynucleotide which is an allelic variant of SEQ ID NO:40;
- (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:161;
- (i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
- 2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

- 3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:161 or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40.
- 4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:40 or the cDNA sequence included in ATCC Deposit No:209782, which is hybridizable to SEQ ID NO:40.
- 5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.
- 7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.
- 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.
 - 9. A recombinant host cell produced by the method of claim 8.
 - 10. The recombinant host cell of claim 9 comprising vector sequences.
- 11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

- (a) a polypeptide fragment of SEQ ID NO:161 or the encoded sequence included in ATCC Deposit No:209782;
- (b) a polypeptide fragment of SEQ ID NO:161 or the encoded sequence included in ATCC Deposit No:209782, having biological activity;
- (c) a polypeptide domain of SEQ ID NO:161 or the encoded sequence included in ATCC Deposit No:209782;
- (d) a polypeptide epitope of SEQ ID NO:161 or the encoded sequence included in ATCC Deposit No:209782;
- (e) a secreted form of SEQ ID NO:161 or the encoded sequence included in ATCC Deposit No:209782;
- (f) a full length protein of SEQ ID NO:161 or the encoded sequence included in ATCC Deposit No:209782;
 - (g) a variant of SEQ ID NO:161;
 - (h) an allelic variant of SEQ ID NO:161; or
 - (i) a species homologue of the SEQ ID NO:161.
- 12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.
- 13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
- 14. A recombinant host cell that expresses the isolated polypeptide of claim 11.
 - 15. A method of making an isolated polypeptide comprising:
- (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and
 - (b) recovering said polypeptide.
 - 16. The polypeptide produced by claim 15.

- 17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.
- 18. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11.
- 19. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the antibody of claim 13.
- 20. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
- 21. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and
- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
- 22. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:
- (a) using the antibody of claim 13 to determine the presence or amount of expression of a polypeptide that specifically binds said antibody; and

- (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
- 23. A method for identifying a binding partner to the polypeptide of claim 11 comprising:
- (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.
- 24. The gene corresponding to the cDNA sequence encoding SEQ ID NO:161.
- 25. A method of identifying an activity in a biological assay, wherein the method comprises:
 - (a) expressing SEQ ID NO:40 in a cell;
 - (b) isolating the supernatant;
 - (c) detecting an activity in a biological assay; and
 - (d) identifying the protein in the supernatant having the activity.
 - 26. The product produced by the method of claim 23.